[CLSTR]
< Back to situation

[REVISION HISTORY]

Merck Lipfendra oral PCSK9 approval

Updated 1 time since CLSTR started tracking revisions of this situation.

What changed

2026-07-25 20:35 UTC → 2026-07-26 18:54 UTC · added removed

The U.S. Food and Drug Administration has confirmed approval of Merck’s Lipfendra (enlicitil‑de), the first once‑daily oral tablet that inhibits the PCSK9 protein. Clinical trials in more than 3,200 adults with primary hypercholesterolemia—including patients on high‑dose statins and those with heterozygous familial hypercholesterolemia—showed average LDL‑cholesterol reductions of about 56 % and up to 59 % in the heterozygous subgroup after 24–28 weeks, with peak reductions near 60 % over six months. A later analysis encompassing over 19,000 participants on statins and lifestyle measures confirmed a similar magnitude of LDL reduction and a favorable safety profile with few side effects. Safety outcomes were comparable to placebo; the most frequent adverse events were dizziness and diarrhea. The drug Lipfendra does not affect lipoprotein(a) levels. Lipfendra is marketed Priced at roughly $315 for a 30‑day supply, markedly supply—considerably lower than the $500‑$600 monthly cost of injectable PCSK9 biologics. The lower price and biologics—the oral administration are tablet is expected to improve adherence and broaden access for the estimated six million Americans eligible for PCSK9‑targeted therapy who currently rely on injectables. therapy. It is intended as an adjunct to diet, exercise, and statin therapy for patients whose LDL remains elevated despite statins or who cannot tolerate statins, and is taken on an empty stomach. The approval builds on decades of PCSK9 research linking loss‑of‑function mutations to reduced LDL expands treatment options beyond statins and cardiovascular risk. injectables, and Merck plans to seek regulatory clearance in other markets such as Brazil.

Versions

  1. 2026-07-26 18:54 UTC Merck Lipfendra oral PCSK9 approval
  2. 2026-07-25 20:35 UTC Merck Lipfendra oral PCSK9 approval

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.